Professor Hilary Calvert
Professor Ruth Plummer
| Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer | 2014 |
|
Professor Ruth Plummer
Dr Evan Mulligan
Professor Nicola Curtin
Professor Hilary Calvert
| A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation | 2013 |
|
Dr Jane Margetts
Dr Yvette Drew
Dr Peter Stephens
Professor Hilary Calvert
Professor Ruth Plummer
| Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5) | 2013 |
|
Professor Ruth Plummer
Professor Hilary Calvert
| Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma | 2013 |
|
Professor Ruth Plummer
Professor Hilary Calvert
| A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors | 2011 |
|
Dr Kappusamy Saravanan
Hannah Barlow
Marion Barton
Professor Hilary Calvert
Emeritus Professor Bernard Golding
et al. | Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1-Acid Glycoprotein | 2011 |
|
Professor Ruth Plummer
Professor Hilary Calvert
| Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas | 2011 |
|
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al. | Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy | 2010 |
|
Dr Peter Stephens
Professor Hilary Calvert
Professor Ruth Plummer
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | 2010 |
|
Professor Hilary Calvert
Professor Ruth Plummer
| Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours | 2010 |
|
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Hilary Calvert
et al. | The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy | 2010 |
|
Amy Quinn
Professor Hilary Calvert
Professor John Lunec
| A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues | 2009 |
|
Professor Hilary Calvert
| A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer | 2009 |
|
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Hilary Calvert
et al. | Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis | 2009 |
|
Professor Hilary Calvert
| Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies | 2009 |
|
